Literature DB >> 2153347

Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction.

W Domagala1, J Lasota, J Bartkowiak, K Weber, M Osborn.   

Abstract

Vimentin expression, growth fractions (GF), and estrogen receptor (ER) levels were determined for 90 untreated primary breast carcinomas. Coexpression of keratin and vimentin was found in approximately 20% of the tumors regardless of menopausal status. Vimentin was expressed preferentially in tumor cells of high-grade ductal breast carcinomas (15 of 28 histologic grade 3 vs. 0 of 40 grades 1 and 2). Vimentin expression was found preferentially in tumors with high GF (greater than 15% Ki-67 positive by immunoperoxidase staining) and low ER levels (less than 60 fmols/mg protein by a monoclonal enzyme immunoassay). Sixty-eight percent of tumors in this group were vimentin positive and 88% of all vimentin-positive tumors fell into this category. More than 50% of the tumor cells coexpressed vimentin and keratin. Thus, vimentin expression may be helpful in identifying a substantial subset of ER-independent breast carcinomas with poor prognostic indicators.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2153347      PMCID: PMC1877466     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  39 in total

1.  Diagnosis of major tumor categories in fine-needle aspirates is more accurate when light microscopy is combined with intermediate filament typing. A study of 403 cases.

Authors:  W Domagala; J Lasota; M Chosia; A Szadowska; K Weber; M Osborn
Journal:  Cancer       Date:  1989-02-01       Impact factor: 6.860

2.  Induction of vimentin synthesis in a murine myeloma cell line by TPA is strongly dependent on the composition of the cell culture medium.

Authors:  G Giese; P Traub
Journal:  Eur J Cell Biol       Date:  1988-12       Impact factor: 4.492

Review 3.  Who needs steroid receptor assays?

Authors:  D M Barnes; I S Fentiman; R R Millis; R D Rubens
Journal:  Lancet       Date:  1989-05-20       Impact factor: 79.321

4.  The distribution of vimentin and keratin in epithelial and nonepithelial neoplasms. A comprehensive immunohistochemical study on formalin- and alcohol-fixed tumors.

Authors:  N Azumi; H Battifora
Journal:  Am J Clin Pathol       Date:  1987-09       Impact factor: 2.493

5.  Co-expression of cytokeratin and vimentin intermediate filament proteins in benign and neoplastic breast epithelium.

Authors:  W A Raymond; A S Leong
Journal:  J Pathol       Date:  1989-04       Impact factor: 7.996

6.  Thymidine labeling index and Ki-67 growth fraction in lesions of the breast.

Authors:  O W Kamel; W A Franklin; J C Ringus; J S Meyer
Journal:  Am J Pathol       Date:  1989-01       Impact factor: 4.307

7.  Growth fractions and estrogen receptors in human breast cancers as determined in situ with monoclonal antibodies.

Authors:  J Gerdes; H Pickartz; J Brotherton; J Hammerstein; H Weitzel; H Stein
Journal:  Am J Pathol       Date:  1987-12       Impact factor: 4.307

8.  An immunoperoxidase study of renal cell carcinomas: correlation with nuclear grade, cell type, and histologic pattern.

Authors:  L J Medeiros; S A Michie; D E Johnson; R A Warnke; L M Weiss
Journal:  Hum Pathol       Date:  1988-08       Impact factor: 3.466

9.  Monoclonal antibody mapping of keratins 8 and 17 and of vimentin in normal human mammary gland, benign tumors, dysplasias and breast cancer.

Authors:  V I Guelstein; T A Tchypysheva; V D Ermilova; L V Litvinova; S M Troyanovsky; G A Bannikov
Journal:  Int J Cancer       Date:  1988-08-15       Impact factor: 7.396

10.  Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki67) in breast carcinoma tissue sections.

Authors:  C Charpin; L Andrac; H Vacheret; M C Habib; B Devictor; M N Lavaut; M Toga
Journal:  Cancer Res       Date:  1988-08-01       Impact factor: 12.701

View more
  36 in total

Review 1.  Vimentin in cancer and its potential as a molecular target for cancer therapy.

Authors:  Arun Satelli; Shulin Li
Journal:  Cell Mol Life Sci       Date:  2011-06-03       Impact factor: 9.261

Review 2.  How malignant is malignant? A brief review of the microscopic assessment of human neoplasms, and the prediction of whether they will metastasize and kill.

Authors:  I Carr; N Pettigrew
Journal:  Clin Exp Metastasis       Date:  1991 Mar-Apr       Impact factor: 5.150

3.  Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior.

Authors:  M J Hendrix; E A Seftor; R E Seftor; K T Trevor
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

Review 4.  Role of intermediate filaments in migration, invasion and metastasis.

Authors:  M J Hendrix; E A Seftor; Y W Chu; K T Trevor; R E Seftor
Journal:  Cancer Metastasis Rev       Date:  1996-12       Impact factor: 9.264

5.  Immunohistochemical profile of invasive lobular carcinoma of the breast: predominantly vimentin and p53 protein negative, cathepsin D and oestrogen receptor positive.

Authors:  W Domagala; M Markiewski; R Kubiak; J Bartkowiak; M Osborn
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

6.  Vimentin expression in benign and malignant breast epithelium.

Authors:  M Heatley; C Whiteside; P Maxwell; P Toner
Journal:  J Clin Pathol       Date:  1993-05       Impact factor: 3.411

7.  Oncogene-induced basement membrane invasiveness in human mammary epithelial cells.

Authors:  E W Thompson; J Torri; M Sabol; C L Sommers; S Byers; E M Valverius; G R Martin; M E Lippman; M R Stampfer; R B Dickson
Journal:  Clin Exp Metastasis       Date:  1994-05       Impact factor: 5.150

8.  Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry. No correlation with survival at 5 years.

Authors:  W Domagala; G Striker; A Szadowska; A Dukowicz; K Weber; M Osborn
Journal:  Am J Pathol       Date:  1992-11       Impact factor: 4.307

9.  Vimentin expression in 98 breast cancers with medullary features and its prognostic significance.

Authors:  S Holck; L Pedersen; T Schiødt; K Zedeler; H Mouridsen
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

10.  Does vimentin help to delineate the so-called 'basal type breast cancer'?

Authors:  Renata U Kusinska; Radzislaw Kordek; Elzbieta Pluciennik; Andrzej K Bednarek; Janusz H Piekarski; Piotr Potemski
Journal:  J Exp Clin Cancer Res       Date:  2009-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.